AstraZeneca: Lynparza (olaparib) and Imfinzi (durvalumab) Combination Reduced Risk of Disease Progression or Death by 37% vs. Chemotherapy and Bevacizumab in Patients With Advanced Ovarian Cancer Without Tumor BRCA Mutations in the DUO-O Phase III Trial
June 05, 2023
June 05, 2023
WILMINGTON, Delaware, June 5 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 3, 2023:
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA(R) (olaparib), IMFINZI(R) (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (c . . .
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA(R) (olaparib), IMFINZI(R) (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (c . . .